title: Effects of the opiate antagonists diprenorphine and naloxone and of selected opiate agonists on feeding behavior in guinea pigs.
abstract: Opiate-sensitive feeding behavior has now been demonstrated in a number of species. We sought information on which opioid receptors might be involved in the observed feeding behaviors. Guinea pigs are known to have higher concentrations of the opioid kappa receptor than any other laboratory animal, so we compared the feeding suppressive potency of the general opiate antagonist, diprenorphine to that of the relatively more mu-specific antagonist, naloxone in that species. We found that diprenorphine was over twenty times more effective than naloxone in suppressing feeding in guinea pigs, suggesting the importance of receptors other than mu in feeding initiation in the guinea pig. Confirmatory evidence for the role of kappa receptors was sought, but not found, in comparisons of the effectiveness of different types of opiate agonists in promoting feeding in these animals. These agonists suppressed, rather than stimulated feeding. We conclude that no feeding stimulatory effects of opiates can be demonstrated in guinea pigs. This observation may indicate that opioids play little role in the natural regulation of feeding in this species or that opioids result in prolonged sedation during which the animals fail to eat. The greater feeding suppressive potency of diprenorphine, a general opiate antagonist, versus naloxone, a mu-preferential antagonist, indicates that to whatever extent opiates are involved in guinea pig feeding, the opiate effect is probably not a mu receptor effect.
authors.affiliation: Department of Medicine, Minneapolis Veteran's Administration Medical Center.
authors.forename: C J
authors.initials: CJ
authors.lastname: Billington
authors.forename: B H
authors.initials: BH
authors.lastname: Herman
authors.forename: T J
authors.initials: TJ
authors.lastname: Bartness
authors.forename: A S
authors.initials: AS
authors.lastname: Levine
authors.forename: J E
authors.initials: JE
authors.lastname: Morley
mesh_terms: D000818:Animals; D002077:Butorphanol / Q000494:pharmacology; D002940:Circadian Rhythm; D003496:Cyclazocine / Q000031:analogs & derivatives / Q000494:pharmacology; D004174:Diprenorphine / Q000494:pharmacology*; D016314:Ethylketocyclazocine / Q000031:analogs & derivatives*; D005247:Feeding Behavior / Q000187:drug effects*; D006168:Guinea Pigs; D009019:Morphinans / Q000494:pharmacology*; D009020:Morphine / Q000494:pharmacology; D009270:Naloxone / Q000494:pharmacology*; D009292:Narcotic Antagonists / Q000494:pharmacology; D009294:Narcotics / Q000378:metabolism; D011957:Receptors, Opioid / Q000187:drug effects; D017473:Receptors, Opioid, kappa; D017450:Receptors, Opioid, mu
chemical_list: D009019:Morphinans; D009292:Narcotic Antagonists; D009294:Narcotics; D011957:Receptors, Opioid; D017473:Receptors, Opioid, kappa; D017450:Receptors, Opioid, mu; D004174:Diprenorphine; D009270:Naloxone; D016314:Ethylketocyclazocine; C012395:ketazocine; D009020:Morphine; D003496:Cyclazocine; D002077:Butorphanol